ライフサイエンスコーパス: thrombopoietic

1 ytokine with potent megakaryocytopoietic and thrombopoietic activities in vivo.

2 We conclude that rhIL-11 has thrombopoietic activity at all doses studied, is well to

3 e-daily, oral TpoR agonist with demonstrated thrombopoietic activity in human subjects, encouraging f

4 Interleukin (IL)-11 is a cytokine with thrombopoietic activity that has been shown to increase

5 everal cell-based assays designed to measure thrombopoietic activity.

6 In this first study of a thrombopoietic agent in children, patients with ITP of >

7 s with a platelet response to Eltrombopag, a thrombopoietic agent, but none responding to an anti-Fcg

8 We asked whether eltrombopag, a thrombopoietic agent, would increase platelet counts, im

9 summarizes the history of the development of thrombopoietic agents and discusses their potential use

10 in ITP patients with low platelet counts on thrombopoietic agents and positively correlated with T-c

11 was cloned and characterized and therapeutic thrombopoietic agents developed.

12 Nonresponders to thrombopoietic agents had increased megakaryocytes but n

13 The second generation of thrombopoietic agents has been shown to correct thromboc

14 A new generation of thrombopoietic agents have had preliminary success in th

15 In conclusion, our findings suggest that thrombopoietic agents in patients with ITP have profound

16 ese data further encourage short-term use of thrombopoietic agents in patients with MYH9-RDs; however

17 Now, a second generation of synthetic thrombopoietic agents including AMG 531 and eltrombopag

18 Clinical trials using thrombopoietic agents to stimulate platelet production h

19 The initial thrombopoietic agents were recombinant and pegylated hum

20 hanisms (e.g. anti-CD20 monoclonal antibody, thrombopoietic agents) have shown promising results in r

21 et counts were elevated after treatment with thrombopoietic agents, the frequency of CD19(+)CD24(hi)C

22 ding 3 who had not persistently responded to thrombopoietic agents.

23 ients were free of blood product support and thrombopoietic agonists.

24 ileukemic agents by virtue of their combined thrombopoietic and antileukemic effects.

25 genitor (GMP) compartments at the expense of thrombopoietic and red cell precursors.

26 Identification of a progenitor with enhanced thrombopoietic capacity would be useful to decipher thes

27 In addition, thrombopoietic cells derived from TSP-DKO mice were more

28 Thus, TSP-deficient thrombopoietic cells function as proangiogenic agents, a

29 Thrombopoietic cells may differentially promote or inhib

30 es of thrombospondins 1 and 2 and that these thrombopoietic cells play key roles in controlling blood

31 ants controlling the angiogenic phenotype of thrombopoietic cells remain unknown.

32 The proangiogenic activity of TSP-DKO thrombopoietic cells was mediated through activation of

33 To determine the relationship of endogenous thrombopoietic cytokine levels and circulating platelet

34 Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates postchemotherapy

35 investigated the mechanism of action of the thrombopoietic cytokine, recombinant human interleukin-1

36 rine circuit wherein increased production of thrombopoietic cytokines in tumor and host tissue leads

37 PO and IL-11, therefore, appear to be active thrombopoietic cytokines regulating, in part, megakaryoc

38 The availability of various thrombopoietic cytokines, in particular thrombopoietin (

39 ith mice transgenic for Pf4-Cre-recombinase (thrombopoietic deletion) or Cd11b-Cre-recombinase (myelo

40 The thrombopoietic efficacy of recombinant forms of c-mpl li

41 The thrombopoietic environment of the neonate is established

42 to peripheral destruction from those due to thrombopoietic failure.

43 Interleukin-11 (IL-11) is a unique thrombopoietic growth factor which causes proliferation

44 tics Institute, Inc, Cambridge, MA), a novel thrombopoietic growth factor, in reducing the need for p

45 Although development of first-generation thrombopoietic growth factors (recombinant human thrombo

46 One or more second-generation thrombopoietic growth factors should soon be clinically

47 All second-generation thrombopoietic growth factors stimulate growth of TPO-de

48 EG-rHuMGDF, nonimmunogenic second-generation thrombopoietic growth factors with unique pharmacologic

49 maintenance of erythrocyte levels following thrombopoietic insult.

50 bocytopenias frequently shed light on normal thrombopoietic mechanisms.

51 series of mutations in exon 12 of JAK2, the thrombopoietic receptor gene MPL, and in the gene encodi

52 We demonstrate that thrombopoietic recovery following myelosuppression was s

53 owever, a comprehensive kinetic study of the thrombopoietic response to a single injection of recombi

54 The effects of thrombopoietic stimulation on megakaryocytopoiesis, plat

55 ic ITP that may be restored in responders to thrombopoietic treatment.